The COPCOV Trial’s position statement on “A living WHO guideline on drugs to prevent COVID-19.”
Following WHO recommendations against the use of hydroxychloroquine in the prevention of COVID-19, including its use in controlled trials, we are reviewing the guideline and available evidence. We are concerned that this judgement from the authors of the guideline is scientifically unsound.
Seroepidemiology of Foot and Mouth Disease using passive surveillance techniques in selected provinces of Lao PDR.
Siengsanan-Lamont J. et al, (2021), Tropical animal health and production, 53
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2021), The Lancet, 397, 1637 - 1645
Estimating the programmatic cost of targeted mass drug administration for malaria in Myanmar.
Kyaw SS. et al, (2021), BMC Public Health, 21